The Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone; Relmada) for the adjunctive treatment of major depressive disorder.

REL-1017 is Relmada’s investigational, rapid-acting, oral N-methyl-D-aspartate (NMDA) receptor antagonist under development for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company has completed a Phase 1 study for REL-1017 and intends to initiate a randomized, double-blind, placebo-controlled Phase 2a trial in patients with major depressive disorder to assess its efficacy, safety, tolerability and pharmacokinetics.

REL-1017, an enantiomer of racemic methadone, exerts its action by inhibiting the activation of NMDA receptors while possessing no opioid activity at therapeutic doses.

Related Articles

Reference

Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder [news release]. New York, NY: Relmada Therapeutics, Inc; released April 13, 2017. http://www.prnewswire.com/news-releases/relmada-announces-fda-fast-track-designation-for-d-methadone-for-adjunctive-treatment-of-major-depressive-disorder-300439275.html. Accessed on May 4, 2017.

This article originally appeared on MPR